Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34936301)

  • 1. Targeting Neuregulin 1 (NRG1): A Novel Biomarker for Non-Small-Cell Lung Cancer.
    Fang C; Kang B; Zhao P; Ran J; Wang L; Zhao L; Luo H; Tao L
    J Environ Pathol Toxicol Oncol; 2021; 40(4):61-72. PubMed ID: 34936301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NRG1 and NRG2 fusions in non-small cell lung cancer (NSCLC): seven years between lights and shadows.
    Trombetta D; Sparaneo A; Fabrizio FP; Di Micco CM; Rossi A; Muscarella LA
    Expert Opin Ther Targets; 2021 Oct; 25(10):865-875. PubMed ID: 34706602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
    Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
    J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
    Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
    World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway.
    Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
    Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
    Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
    Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2.
    Li Z; Qu L; Zhong H; Xu K; Qiu X; Wang E
    Oncol Rep; 2014 Apr; 31(4):1707-14. PubMed ID: 24573418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
    Mendell J; Freeman DJ; Feng W; Hettmann T; Schneider M; Blum S; Ruhe J; Bange J; Nakamaru K; Chen S; Tsuchihashi Z; von Pawel J; Copigneaux C; Beckman RA
    EBioMedicine; 2015 Mar; 2(3):264-71. PubMed ID: 26137564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Rab17 promotes cell proliferation and invasion in non-small cell lung cancer through STAT3/HIF-1α/VEGF signaling.
    Wang M; Wang W; Ding J; Wang J; Zhang J
    Thorac Cancer; 2020 Feb; 11(2):379-388. PubMed ID: 31841274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
    Liu J; Han Y; Liu X; Wei S
    Technol Cancer Res Treat; 2020; 19():1533033820973276. PubMed ID: 33251978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 16. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.
    Ke H; Shen W; Hu A; Ou Q; Lu S
    J Thorac Oncol; 2019 Dec; 14(12):e263-e266. PubMed ID: 31757375
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical significance and diagnostic value of Survivin autoantibody in non-small cell lung cancer patients].
    Ma L; Yue W; Zhang L; Wang Y; Zhang C; Yang X
    Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):706-12. PubMed ID: 20673487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.
    Khandelwal A; Seam RK; Gupta M; Rana MK; Prakash H; Vasquez KM; Jain A
    Cancer Sci; 2020 Mar; 111(3):826-839. PubMed ID: 31520555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.